Inhaled insulin - what went wrong

被引：20

作者：

Mitri, Joanna ^{[2
]}

Pittas, Anastassios G. ^{[1
]}

机构：

[1] Tufts Med Ctr, Div Endocrinol Diabet & Metab, Boston, MA 02111 USA

[2] Roger Williams Gen Hosp, Providence, RI 02908 USA

来源：

NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM | 2009年 / 5卷 / 01期

关键词：

THERAPY;

D O I：

10.1038/ncpendmet1007

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

FDA approval of inhaled insulin offered the possibility of a new direction in diabetes care. Nonetheless, within a year of coming to market, the first inhaled insulin product was withdrawn by the manufacturer. Here, Mitri and Pittas examine the factors behind the failure of inhaled insulin to be adopted by patients and clinicians.

引用

页码：24 / 25

页数：2

共 6 条

[1]

BERENSON A, 2007, WEAK SALES PROMPT PF

[2] Meta-analysis: Efficacy and safety of inhaled insulin therapy in adults with diabetes mellitus [J].

Ceglia, Lisa ;

Lau, Joseph ;

Pittas, Anastassios G. .

ANNALS OF INTERNAL MEDICINE, 2006, 145 (09) :665-675

[3] An assessment of eligibility for inhaled insulin (exubera) - The Fremantle diabetes study [J].

Davis, Timothy M. E. ;

Davis, Wendy A. .

DIABETES CARE, 2007, 30 (02) :360-361

[4] Ten lessons for evidence-based technology assessment [J].

Eisenberg, JM .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (19) :1865-1869

[5] Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with type 2 diabetes [J].

Freemantle, N ;

Blonde, L ;

Duhot, D ;

Hompesch, M ;

Eggertsen, R ;

Hobbs, FDR ;

Martinez, L ;

Ross, S ;

Bolinder, B ;

Stridde, E .

DIABETES CARE, 2005, 28 (02) :427-428

[6]

EXUBERA LABELING UPD

← 1 →